Key result
Pharmacologic treatment of primary and secondary pulmonary hypertension requires an understanding of pathophysiology, potential benefits, and toxicities of specific agents for individual patients.
A review of the pathophysiology, consequences, and pharmacologic treatment options for primary and secondary pulmonary hypertension.
Individualized pulmonary hypertension therapy remains essential; leaves open optimal agent selection for future trials.
A variety of diseases are associated with elevation of pressure within the pulmonary circulation. Pulmonary hypertension is considered a contributor to the morbidity and mortality associated with these conditions. An understanding of the pathophysiology and consequences of pulmonary hypertension is required when considering pharmacologic treatment. Information regarding the potential benefits and toxicities of the drug therapy for primary and secondary hypertension is necessary when considering the use of specific agents for an individual patients.
No takes yet. Share an insight, caveat, or question.
Glen Brown (1991) conducted a review in Primary and secondary pulmonary hypertension. Pharmacologic treatment was evaluated. Pharmacologic treatment of primary and secondary pulmonary hypertension requires an understanding of pathophysiology, potential benefits, and toxicities of specific agents for individual patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: